COVID-19 is Disrupting Some Alzheimer’s Clinical Trials
By Phil Gutis | March 25th, 2020
The response was disappointing but not particularly surprising. Earlier in the day, I had sent a quick email to check in with the staff…
First Patient Receives Biogen’s Alzheimer’s Drug, Aducanumab, in New Trial
By Phil Gutis | March 13th, 2020
Being Patient Senior Reporter Phil Gutis spent the day with our patient advisor, Jeff Borghoff, who was the first recipient in Biogen’s latest trial…
A ‘Medical Emergency’: Experts Project Alzheimer’s Cases Will Triple by 2050
By Phil Gutis | March 12th, 2020
Barring any medical breakthroughs, the Alzheimer’s Association is warning that the number of cases of people living with Alzheimer’s may nearly triple by 2050….
Harnessing the Brain’s Immune Cells to Remove Amyloid Plaques in Alzheimer’s
By Phil Gutis | March 10th, 2020
Researchers in Germany and San Francisco believe they have identified an antibody that binds to the brain’s immune cells and causes them to live…
People With Dementia Are at Higher Risk of Coronavirus: Here’s How to Prepare
By Phil Gutis | March 4th, 2020
With concerns about the coronavirus spreading around the U.S., people living with Alzheimer’s or other dementias, as well as their caregivers, should be aware…
Biogen Spends $350 Million to Develop Gene Therapies For Alzheimer’s, Parkinson’s
By Phil Gutis | March 3rd, 2020
Frustrated for decades with failure after failure in efforts to find effective medications to treat Alzheimer’s and other cognitive disorders, researchers are now increasingly…
When Alzheimer’s Trials Are Cancelled: Notifying Study Participants in the Most ‘Humane’ Way
By Phil Gutis | February 28th, 2020
Almost a year ago, the phones and social media feeds of about 4,000 people around the world began to explode. Biogen had unexpectedly—and quite…
Follow us